- Home
- OCFC vs PRTA Comparison
OCFC vs PRTA Comparison
Compare OCFC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- PRTA
- Stock Information
- Founded
- OCFC 1902
- PRTA 2012
- Country
- OCFC United States
- PRTA Ireland
- Employees
- OCFC N/A
- PRTA N/A
- Industry
- OCFC Major Banks
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- PRTA Health Care
- Exchange
- OCFC Nasdaq
- PRTA Nasdaq
- Market Cap
- OCFC 861.7M
- PRTA 809.8M
- IPO Year
- OCFC 1996
- PRTA N/A
- Fundamental
- Price
- OCFC $16.81
- PRTA $4.59
- Analyst Decision
- OCFC Buy
- PRTA Buy
- Analyst Count
- OCFC 4
- PRTA 9
- Target Price
- OCFC $21.25
- PRTA $27.67
- AVG Volume (30 Days)
- OCFC 281.4K
- PRTA 2.8M
- Earning Date
- OCFC 07-17-2025
- PRTA 05-08-2025
- Dividend Yield
- OCFC 4.76%
- PRTA N/A
- EPS Growth
- OCFC N/A
- PRTA N/A
- EPS
- OCFC 1.53
- PRTA N/A
- Revenue
- OCFC $369,879,000.00
- PRTA $137,935,000.00
- Revenue This Year
- OCFC N/A
- PRTA N/A
- Revenue Next Year
- OCFC $12.29
- PRTA $122.59
- P/E Ratio
- OCFC $10.99
- PRTA N/A
- Revenue Growth
- OCFC N/A
- PRTA 54.55
- 52 Week Low
- OCFC $14.03
- PRTA $4.32
- 52 Week High
- OCFC $21.87
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- OCFC 49.27
- PRTA 19.53
- Support Level
- OCFC $16.58
- PRTA $4.32
- Resistance Level
- OCFC $17.70
- PRTA $4.94
- Average True Range (ATR)
- OCFC 0.42
- PRTA 0.52
- MACD
- OCFC -0.08
- PRTA -0.15
- Stochastic Oscillator
- OCFC 24.84
- PRTA 7.24
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).